ccx559
chemocentryx
['ccx,559', '$ccxi', 'chemocentryx']
$ccxi chemocentryx reports safety results available from ongoing phase i trial of orally administered pd-l1 inhibitor, ccx559, at the 2022 american society of clinical oncology (asco) annual meeting 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities